

Combo Tx Better for Bipolar Relapse Prevention

BY BRUCE JANCIN

FROM THE ANNUAL INTERNATIONAL CONGRESS
OF THE ROYAL COLLEGE OF PSYCHIATRISTS

EDINBURGH — Long-term combination therapy with lithium plus valproate in patients with bipolar I disorder was markedly more effective than valproate monotherapy in randomized trial.

BALANCE (Bipolar Affective Disorder: Lithium Anticonvulsant Evaluation)

will be a practice-changing study, both in the United States and in the United Kingdom, where it originated, study coordinator and chief investigator Dr. John R. Geddes predicted at the congress.

"As valproate monotherapy is substantially the most commonly used treatment in the United States, BALANCE should probably lead to some change in practice over there. ... I think BALANCE would suggest that for a majority of pa-

tients, combination therapy would be a better bet than valproate monotherapy. And even lithium might be better as a first-line therapy," commented Dr. Geddes, professor of epidemiological psychiatry and a senior clinical research fellow at the University of Oxford (England).

BALANCE included 330 patients aged 16 and older with bipolar I disorder at 41 sites in the United Kingdom, France, the United States, and Italy who were ran-

domized to open-label lithium monotherapy at a target dose of 0.4-1.0 mmol/L, to valproate monotherapy at 750-1,250 mg/day, or to both agents in combination.

The primary outcome was emergence of a new mood episode requiring further intervention (defined as either another medication or hospitalization) during 2 years of follow-up. This occurred in 69% of the valproate group, 59% of those taking lithium, and 54% on combination

For patients with type 2 diabetes whose blood glucose is uncontrolled with orals alone

**THIS IS NOT JUST A TIRE
IT'S SOMETHING WE TAKE
FOR GRANTED UNTIL IT'S
WEARING OUT**



Important Safety Information for Lantus® (insulin glargine [rDNA origin] injection) (cont'd)

Warnings and Precautions (cont'd)

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur.

A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

Please see additional Important Safety Information for Lantus® continued on the next page.

Learn more at www.RethinkInsulin.com

sanofi aventis
Because health matters

therapy (Lancet 2010;375:385-95).

Thus, combination therapy resulted in a 41% relative risk reduction in the primary end point compared with valproate monotherapy, and an 18% reduction compared with lithium. Lithium monotherapy achieved a 39% relative risk reduction compared with valproate.

The time to a 10% hospitalization rate averaged 4.7 months in the valproate group, 7.7 months with lithium, and 11.3 months with combination therapy.

“You may well want to put patients on combination therapy before they’ve had the chance to fail on monotherapy, in the

same way that in cancer therapy we often use combination therapy right from



Combination therapy ‘really gives you the best chance of controlling the condition.’

DR. GEDDES

day 1. It really gives you the best chance of controlling the condition,” he said.

In terms of numbers needed to treat (NNT), BALANCE showed that seven bipolar patients would need to receive combination therapy for 2 years instead of valproate for there to be one fewer relapse; that’s a very favorable NNT, Dr. Geddes observed. The NNT was 10 for lithium vs. valproate, and 20 for combination therapy vs. lithium monotherapy.

“We can neither refute nor confirm an added benefit for combination therapy over lithium alone,” Dr. Geddes said. “The trial would have to be quite a lot larger to pick up any added benefit.”

No baseline predictors of individual

treatment response could be identified. Genotype data are now being analyzed. “The results so far aren’t overly impressive, so don’t hold your breath on that one,” he advised.

The BALANCE trial was funded by the Stanley Medical Research Institute, with donation of drugs by Sanofi-Aventis.

Dr. Geddes disclosed having received research funds from the Medical Research Council, the Economic and Social Research Council, and the National Institute for Health Research, as well as the Stanley Medical Research Institute. ■

ADVERTISEMENT



JUST LIKE THE PANCREAS

By the time of diagnosis, patients may have lost up to 50% of β -cell function, and it may continue to decline, on average, by approximately 5% annually.¹

Patients may not know that their pancreas is no longer making enough insulin and that their disease has progressed.²

Based on data from 2003-2004, about 40% of patients with diabetes nationwide were not adequately controlled^a—and may have spent an average of 5 years with an A1C >8% from diagnosis to insulin initiation.^{3,4}

You may be surprised that in a survey, about 80% of patients with type 2 diabetes taking oral antidiabetic drugs said they would consider taking insulin based on your recommendation.⁵

Patients may focus on blaming themselves for their uncontrolled blood glucose, but you can help them focus on turning this negative mindset into positive action for managing their disease.²

Insulin may help make a difference. Insulin is an effective medication for lowering blood glucose levels. It works as part of an overall treatment plan.^b

So, consider prescribing insulin today to help lower blood glucose for your appropriate patients.

Important Safety Information for Lantus[®] (insulin glargine [rDNA origin] injection) (cont’d)

Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse Reactions

Other adverse reactions commonly associated with Lantus[®] are injection site reaction, lipodystrophy, pruritus, and rash.

Please see brief summary of full prescribing information for Lantus[®] on the following pages.

^aGlucose control defined as A1C <7%.

^bIncluding diet, exercise, and other diabetes medications.

References: 1. Holman RR. *Diabetes Res Clin Pract.* 1998;40(suppl):S21-S25. 2. Polonsky WH, Jackson RA. *Clin Diabetes.* 2004;22(3):147-150. 3. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. *Diabetes Care.* 2008;31(1):81-86. 4. Brown JB, Nichols GA, Perry A. *Diabetes Care.* 2004;27(7):1535-1540. 5. Data on file, sanofi-aventis U.S. LLC.

INSULIN
IMPROVING BLOOD GLUCOSE CONTROL SHOULDN'T WAIT